Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 7675 results

  1. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

    Interventional procedures guidance
    Discontinued

  2. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  3. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  4. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

    Interventional procedures guidance
    Discontinued

  7. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued [GID-MT557]

    Medical technologies guidance
    Discontinued

  8. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued [GID-MT563]

    Medical technologies guidance
    Discontinued

  9. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  11. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]

    In development [GID-TA11007] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Technology appraisal guidance
    Published
    12 May 2021

  15. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development [GID-TA11475] Expected publication date: TBC

    Technology appraisal guidance
    In development